Investor's Business Daily on MSN2h
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
globes.co.il5h
Can Teva sustain its comeback?
Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...
BioSpace13hOpinion
Opinion: Drugs Are Becoming ‘smarter.’ Here’s How
I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...
Business Insider17h
Teva Pharmaceutical (TEVA) Gets a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...